OTC · Medical - Diagnostics & Research

BioMark Diagnostics Inc. (BMKDF) Stock

$0.38 +0.00% OTC: BMKDF Healthcare

BioMark Diagnostics Inc. is an oncology-focused firm that develops sophisticated diagnostic tools for cancer.

Valuation

MetricValue
Price$0.38
Market Cap$40.21M
P/E Ratio-31.98
P/B Ratio113.77
P/S Ratio629.82
EPS (TTM)$-0.02
52-Week High$0.50
52-Week Low$0.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-153.00%
ROA-79.58%
ROCE-211.06%
Gross Margin-147.92%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity1.40
Current Ratio1.20

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-1.0M$-2.0M$-1.0M$-2.0M
Net Profit$-1.0M$-1.0M$-2.0M$-1.0M$-2.0M
EPS$-0.01$-0.02$-0.02$-0.02$-0.02
Op Margin—-3193.7%-1128.4%-806.1%-1237.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.0M$1.0M$1.0M$1.0M$3.0M
Total Liabilities$1.0M$2.0M$2.0M$2.0M$1.0M
Cash$1.0M$0$0$0$2.0M
Borrowings$0$1.0M$2.0M$2.0M$0

Latest News

Biomark Diagnostics Gets Canadian, European Patent Allowances for Early-Stage Lung Cancer Blood Test MT Newswires · Jun 23, 2026 BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test TMX Newsfile · Jun 23, 2026 BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform TMX Newsfile · Jun 9, 2026 3 European Penny Stocks With Market Caps Over €40M To Watch Simply Wall St. · May 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-1.0M$-1.0M$-1.0M$-1.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$1.0M$1.0M$0$0$0
Net Cash Flow$0$0$0$0$2.0M
Free Cash Flow$-1.0M$-1.0M$-1.0M$-1.0M$-1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.63
EV / EBITDA-44.97
FCF Yield-3.55%
Quick Ratio1.20
Interest Coverage-38.39
Return 1Y58.03%
Return 3Y101.46%
Return 5Y137.48%

Ownership

Insiders Held48.46%
Institutions Held0.00%
Institutions Float Held0.00%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLIFFCordlife Group Limited $0.09 -40.12% -3.10 $23.09M 0.00%
CLYYFCelyad Oncology S.A. $0.20 +0.00% 14.03 $8.95M 0.00%
CNTMFFluent Corp. $0.02 +8.33% -0.17 $10.35M 0.00%
DGNOFDIAGNOS Inc. $0.20 +0.76% -6.78 $24.08M 0.00%
ELVAFEvoNext Holdings S.A. $2.15 +0.00% -23.56 $15.50M 0.00%

About BioMark Diagnostics Inc.

BioMark Diagnostics Inc. is an oncology-focused firm that develops sophisticated diagnostic tools for cancer. These solutions are designed to aid in the identification of the disease, its ongoing monitoring, and the assessment of initial therapeutic interventions. The company has a research partnership with the Icahn School of Medicine, under which they conduct clinical studies concentrating on the early detection of lung cancer. Established in 2014, BioMark Diagnostics Inc. has its main office in Richmond, Canada, and functions as a subsidiary of Biomark Technologies Inc.

BioMark Diagnostics Inc. is headquartered in CA.

BioMark Diagnostics Inc. (BMKDF) stock trades at $0.38 with a market capitalization of $40.21M. The stock is valued at a price-to-earnings (P/E) ratio of -31.98, price-to-book of 113.77, price-to-sales of 629.82. Over the past 52 weeks the stock has ranged between $0.21 and $0.50, and currently trades 24.0% below its 52-week high.

On profitability, BioMark Diagnostics Inc. generates a return on equity (ROE) of -153.00%, return on capital employed of -211.06%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.biomarkdiagnostics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides